353 related articles for article (PubMed ID: 19817890)
1. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Fareed KR; Ilyas M; Kaye PV; Soomro IN; Lobo DN; Parsons SL; Madhusudan S
Histopathology; 2009 Oct; 55(4):399-406. PubMed ID: 19817890
[TBL] [Abstract][Full Text] [Related]
2. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
[TBL] [Abstract][Full Text] [Related]
3. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
4. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
5. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.
Fareed KR; Al-Attar A; Soomro IN; Kaye PV; Patel J; Lobo DN; Parsons SL; Madhusudan S
Br J Cancer; 2010 May; 102(11):1600-7. PubMed ID: 20461087
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction.
Forshaw MJ; Gossage JA; Chrystal K; Cheong K; Atkinson S; Botha A; Harper PG; Mason RC
Eur J Surg Oncol; 2006 Dec; 32(10):1114-8. PubMed ID: 16621430
[TBL] [Abstract][Full Text] [Related]
7. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV
J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520
[TBL] [Abstract][Full Text] [Related]
10. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
Strickland AH; Karapetis CS; Yip D; Harper PG
Clin Oncol (R Coll Radiol); 2001; 13(1):66. PubMed ID: 11292143
[No Abstract] [Full Text] [Related]
12. Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
Geh JI; Glynne-Jones R; Kwok QS; Banerji U; Livingstone JI; Townsend ER; Harrison RA; Mitchell IC
Clin Oncol (R Coll Radiol); 2000; 12(3):182-7. PubMed ID: 10942336
[TBL] [Abstract][Full Text] [Related]
13. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
Noble F; Lloyd MA; Turkington R; Griffiths E; O'Donovan M; O'Neill JR; Mercer S; Parsons SL; Fitzgerald RC; Underwood TJ;
Br J Surg; 2017 Dec; 104(13):1816-1828. PubMed ID: 28944954
[TBL] [Abstract][Full Text] [Related]
14. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
15. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
Smyth EC; Fassan M; Cunningham D; Allum WH; Okines AF; Lampis A; Hahne JC; Rugge M; Peckitt C; Nankivell M; Langley R; Ghidini M; Braconi C; Wotherspoon A; Grabsch HI; Valeri N
J Clin Oncol; 2016 Aug; 34(23):2721-7. PubMed ID: 27298411
[TBL] [Abstract][Full Text] [Related]
16. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
Larsen AC; Holländer C; Duval L; Schønnemann K; Achiam M; Pfeiffer P; Yilmaz MK; Thorlacius-Ussing O; Bæksgaard L; Ladekarl M
Ann Surg Oncol; 2015 May; 22(5):1540-7. PubMed ID: 25348777
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
18. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases.
Becker K; Langer R; Reim D; Novotny A; Meyer zum Buschenfelde C; Engel J; Friess H; Hofler H
Ann Surg; 2011 May; 253(5):934-9. PubMed ID: 21490451
[TBL] [Abstract][Full Text] [Related]
19. [Preliminary results of neoadjuvant treatment of adenocarcinoma of the gastro-esophageal junction].
Pedrazzani C; Pasini F; Giacopuzzi S; Bernini M; Gabbani M; Grandinetti A; Tomezzoli A; Ruzzenente A; Guglielmi A; de Manzoni G
Chir Ital; 2005; 57(1):9-14. PubMed ID: 15832733
[TBL] [Abstract][Full Text] [Related]
20. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
Mansour JC; Tang L; Shah M; Bentrem D; Klimstra DS; Gonen M; Kelsen DP; Brennan MF; Coit DG
Ann Surg Oncol; 2007 Dec; 14(12):3412-8. PubMed ID: 17909917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]